ETNB 8.35 (+1.71%)
US2825591033BiotechnologyBiotechnology

89bio (ETNB) Stock Highlights

8.35 | +1.71%
2024-10-21 03:01:54
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Statistics

Range Today
8.17 8.76
Volume Today 489.8K
Range 1 Year
6.57 16.63
Volume 1 Year 269.8M
Range 3 Year
2 22.93
Volume 3 Year 755.18M
Range 10 Year
2 47.253
Volume 10 Year 810.39M

Highlights

Market Capitalization 884.35M (small)
Floating Shares 67.93M
Current Price 8.35
Price To Earnings -4.2
Price To Book 1.7
Earnings Per Share -1.96
Payout Ratio 0%

Performance

Latest +1.71%
1 Month -1.65%
3 Months -4.24%
6 Months -8.74%
1 Year +17.61%
3 Years -53.77%
5 Years -58.25%
10 Years -58.25%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.